1. Home
  2. CMPS vs SGP Comparison

CMPS vs SGP Comparison

Compare CMPS & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COMPASS Pathways Plc American Depository Shares

CMPS

COMPASS Pathways Plc American Depository Shares

HOLD

Current Price

$6.14

Market Cap

778.7M

Sector

Health Care

ML Signal

HOLD

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$27.19

Market Cap

932.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CMPS
SGP
Founded
2020
2019
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
778.7M
932.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CMPS
SGP
Price
$6.14
$27.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$27.14
$45.00
AVG Volume (30 Days)
4.4M
87.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
0.86
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.25
$24.71
52 Week High
$8.90
$30.56

Technical Indicators

Market Signals
Indicator
CMPS
SGP
Relative Strength Index (RSI) 40.28 54.53
Support Level $5.95 $25.66
Resistance Level $7.02 $29.71
Average True Range (ATR) 0.46 1.66
MACD -0.12 -0.11
Stochastic Oscillator 3.82 47.23

Price Performance

Historical Comparison
CMPS
SGP

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Share on Social Networks: